Welcome to our dedicated page for Lifestance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for LifeStance Health Group, Inc. (Nasdaq: LFST), a mental healthcare company focused on outpatient services. As a public company with common stock registered on The Nasdaq Stock Market LLC, LifeStance files documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.
LifeStance’s filings offer detailed information about its business as one of the nation’s largest providers of virtual and in-person outpatient mental healthcare. In these documents, the company describes its operations, risk factors, financial condition and results of operations. For example, current reports on Form 8-K have been used to furnish earnings press releases for specific quarters and to disclose changes in the board of directors, including director resignations and appointments with related equity awards under the company’s equity incentive plan.
Investors can review LifeStance’s discussion of non-GAAP financial measures such as Center Margin and Adjusted EBITDA, along with reconciliations to comparable GAAP measures, within its filings and related exhibits. The company also outlines forward-looking statements and associated risks, referring readers to the "Risk Factors" section of its Form 10-K and subsequent filings for more comprehensive risk disclosures.
On Stock Titan, LifeStance filings are updated as new documents are made available through the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy filings, highlight significant changes from prior periods and clarify technical language. Users can quickly identify items related to quarterly and annual results, governance events reported on Form 8-K and other regulatory disclosures relevant to LFST, while still having access to the full original documents for detailed review.
Insider sale by Summit Partners entities: On 08/18/2025 multiple Summit-related entities reported an aggregate sale of 8,407,643 shares of LifeStance Health Group, Inc. (LFST) at a price of $5.07 per share. After the reported transactions, the entities collectively beneficially own 33,524,715 shares held across five Summit funds and entities. The filings identify Summit Partners, L.P. as the manager with voting and dispositive authority exercised by a four-person investment committee. The report was signed and filed on 08/20/2025 by authorized representatives of the Summit entities.
LifeStance Health Group, Inc. (LFST) filed a Form 144 notifying a proposed sale of 894,098 shares of Common Stock through Morgan Stanley & Co. LLC, with an aggregate market value of $4,837,070.18. The filing lists the approximate date of sale as 08/18/2025 and the securities exchange as NASDAQ.
The shares were acquired pre-IPO on 06/10/2021 from the issuer, with 5,130,460 shares originally acquired on that date. The filer reports no securities sold in the past three months and includes the required certification that no undisclosed material adverse information is known.
LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 2,471,741 shares of common stock through Morgan Stanley & Co. LLC with an aggregate market value of $13,372,118.81. The filing lists approximately 388,936,394 shares outstanding and an approximate sale date of 08/18/2025 on NASDAQ. The securities to be sold were originally acquired on 06/10/2021 in pre-IPO transactions, with 14,183,201 shares reported as acquired at that time. The filer certifies they are unaware of undisclosed material adverse information about the issuer.
LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 226,518 shares of common stock through Morgan Stanley & Co. LLC on 08/18/2025. The filing states an aggregate market value of $1,225,462.38 and reports 388,936,394 shares outstanding. The securities were acquired in a pre-IPO transaction on 06/10/2021, when 1,299,792 shares were obtained from the issuer; payment is noted as equity interests purchased pre-IPO. No sales by the reporting person in the past three months are disclosed. The filer certifies they are unaware of undisclosed material adverse information about the issuer.
LifeStance Health Group, Inc. (LFST) filed a Form 144 disclosing a proposed sale of 3,214,648 shares of Common Stock through Morgan Stanley & Co. LLC on 08/18/2025 on NASDAQ, with an aggregate market value of $17,391,245.68. The shares were originally acquired 06/10/2021 in a pre-IPO transaction from LifeStance Health Group Inc.; the filing reports total outstanding shares of 388,936,394. The filer certifies there is no undisclosed material adverse information and notes no securities were sold by the filer in the past three months.
LifeStance Health Group, Inc. (LFST) submitted a Form 144 notice for a proposed sale of securities under Rule 144. The filing shows 5,148,494 shares of Common Stock are planned to be sold through Morgan Stanley & Co. LLC on or about 08/18/2025, with an aggregate market value of $27,853,352.54 and 388,936,394 shares outstanding. The securities were acquired on 06/10/2021 in a pre-IPO transaction, totaling 29,542,786 shares acquired on that date. No securities were reported sold in the past three months. The filer certifies they do not possess undisclosed material adverse information about the issuer.
LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 4,804 shares of common stock through Morgan Stanley & Co. LLC on approximately 08/18/2025. The filing lists an aggregate market value of $25,989.64 and indicates 388,936,394 shares outstanding. The shares were originally acquired on 06/10/2021 in a pre-IPO transaction from LifeStance Health Group Inc., with 27,568 shares noted as acquired at that time. No securities were reported sold in the past three months. The filer certifies they are not aware of undisclosed material adverse information about the issuer and the notice is marked LIVE.
LifeStance Health Group, Inc. (LFST) Form 144 notifies the market of a proposed sale of 35,938 shares of common stock through Morgan Stanley & Co. LLC, with an aggregate market value of $194,424.58. The filing states the securities will be sold approximately on 08/18/2025 on NASDAQ and shows 388,936,394 shares outstanding. The shares were originally acquired 06/10/2021 in a pre-IPO transaction (206,219 shares acquired) from LifeStance Health Group Inc. No sales by the seller are reported in the past three months.
LifeStance Health Group, Inc. (LFST) filed a Form 144 notifying a proposed sale of 3,759 shares of Common Stock through Morgan Stanley & Co. LLC with an aggregate market value of $20,336.19. The filing lists approximately 388,936,394 shares outstanding and an approximate sale date of 08/18/2025.
The shares were originally acquired 06/10/2021 in pre-IPO transactions from LifeStance Health Group Inc.; the filer reported acquiring 21,572 shares on that date. The notice states there were no securities sold by the account in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Kenneth A. Burdick, a director of LifeStance Health Group, Inc. (LFST), reported multiple open-market purchases of common stock on August 8 and August 11, 2025. The filings show acquisitions totaling 67,670 shares at prices between $4.30 and $4.54. After these transactions his reported direct beneficial ownership rose to 3,436,571 shares, and he also holds 46,511 shares indirectly through Burdick Family LLC.